India's Weight-Loss Drug Market Booms Amid GLP-1 Frenzy

The Indian market for GLP-1 weight-loss drugs reached ₹2,215 crore in MAT sales by July, driven by a surge in demand for semaglutide generics.

Pharmaceutical firms are racing to build businesses around this trend, with multiple brands competing for market share in the diabetes and obesity sector.

Health experts emphasize the importance of quality control in these medications to ensure long-term safety for patients managing diabetes and weight-related conditions.